ID: 151: Unique and overlapping roles of type I and type III interferons in influenza pathology and therapy
Type I and type III interferons (IFN α β and IFN λ ) are key antiviral cytokines. In addition, IFN α β is increasingly recognised as potentially disease-promoting in infection. We explored the roles of these IFN families in influenza infection and as anti-influenza treatment. When comparing influenza-infected 129 to C57BL/6 mouse strains, we found increased lung damage, morbidity and mortality, yet higher levels of IFN α β , in 129 mice than in the more resistant C57BL/6 mice. IFN α β receptor deficiency in 129 mice decreased morbidity and lung damage, and ameliorated immune-mediated tissue damage, indicating that IFN α β levels are a host determinant of influenza severity. In contrast, the respiratory epithelial anti-influenza response was unaffected by IFN α β receptor deficiency, as IFN λ replaced IFN α β in these cells. Lack of IFN α β signalling reduced expression of the death-inducing receptor DR5 on lung epithelia and its ligand TRAIL on inflammatory monocytes, and depletion of PDCA-1+ cells or interruption of TRAIL-DR5 interaction protected infected 129 mice. Therefore, excessive IFN α β signalling in response to acute influenza infection may explain morbidity. Our results suggest that humans with propensity to strong IFN α β signalling may be at risk of severe influenza. We assessed the implications of our results for influenza treatment, using C57BL/6 mice with a functional Mx1 allele. Treatment with either IFN α 4 or IFN λ 2 prior to infection blocked influenza replication and protected against host morbidity and mortality. In contrast, outcome of IFN treatment during influenza infection was divergent. Results of IFN therapy will be presented and discussed in the context of treatment options for influenza in humans.